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Abstract: Standards of care for meningioma include surgical resection and radiotherapy whereas phar-
macotherapy plays almost no role in this disease. We generated primary cultures from surgically removed
meningiomas to explore the activity of a novel cyclin-dependent kinase inhibitor, TG02, in meningioma
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profiling. DNA methylation data were used to allot each sample to one out of six previously established
meningioma methylation classes: benign (ben)-1, 2, 3, intermediate (int)-A, B, and malignant (mal).
Four tumors assigned to the methylation class ben-2 showed the same class in culture whereas cultures
from five non-ben-2 tumors showed a more malignant class in four patients. Cell cultures were uniformly
sensitive to TG02 in the nanomolar range. Assignment of the cell cultures to a more malignant methy-
lation class appeared to be more closely associated with TG02 sensitivity than assignment to a higher
WHO grade of the primary tumors. Primary cell cultures from meningioma facilitate the investigation of
the anti-meningioma activity of novel agents. TG02, an orally available cyclin-dependent kinase (CDK)
inhibitor, warrants further exploration.
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Standards of care for meningioma include surgical resection and radiotherapy whereas pharmacotherapy plays almost
no role in this disease. We generated primary cultures from surgically removed meningiomas to explore the activity of
a novel cyclin-dependent kinase inhibitor, TG02, inmeningioma cell cultures. Tumor and cell cultures were character-
ized by mutation profiling and DNA methylation profiling. DNA methylation data were used to allot each sample to
one out of six previously established meningioma methylation classes: benign (ben)-1, 2, 3, intermediate (int)-A, B,
and malignant (mal). Four tumors assigned to the methylation class ben-2 showed the same class in culture whereas
cultures from five non-ben-2 tumors showed a more malignant class in four patients. Cell cultures were uniformly sen-
sitive to TG02 in the nanomolar range. Assignment of the cell cultures to amoremalignant methylation class appeared
to be more closely associated with TG02 sensitivity than assignment to a higher WHO grade of the primary tumors.
Primary cell cultures from meningioma facilitate the investigation of the anti-meningioma activity of novel agents.
TG02, an orally available cyclin-dependent kinase (CDK) inhibitor, warrants further exploration.
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Meningiomas are the most common primary intracranial tumors [1].
The revisedWHOclassification of tumors of the central nervous system rec-
ognizes three grades of malignancy for meningiomas with nine histological
variants for grade I tumors, three variants for grade II tumors, and three var-
iants for grade III tumors [2]. WHO grade I meningiomas represent approx-
imately 90% of these tumors. Many of these are incidentally detected and
may need no intervention. In contrast, WHO grade II (7%) and III (3%) tu-
mors are less common, but notably grade III meningiomas are aggressive tu-
mors that can be lethal within a few years despite aggressive multimodality
treatment. The histological variants within the different grades of meningi-
omas provide little prognostic information and subgroups of meningiomas
behave different from what would be predicted by their grade assignment,
that is, some grade I tumors progress rapidly despite adequate treatment
whereas some grade II and more rarely grade III tumors show a more be-
nign course than expected [3]. These shortcomings of the purely morpho-
logical classification of meningiomas in the current WHO classification
may be overcome by genomic methylation profiling that has allowed to de-
lineate six prognostic classes of meningiomas referred to as ben-1, 2, 3, int-
A, int-B, andmal [4]. Classifiers based onmethylation profilingmay provide
superior prognostic information for individual patient counseling and for
patient stratification in clinical trials [4,5].
Surgery and radiotherapy are the standard treatments formeningiomas.
The majority of grade I meningiomas can probably be cured by surgery
alone. Incompletely resected WHO grade I meningiomas can be followed
and irradiated if symptomatic or at further progression. The role of imme-
diate radiotherapy after complete resection of WHO grade II meningiomas
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remains controversial and is being addressed in randomized clinical trials.
WHO grade III meningiomas tend to respond only transiently to surgery
followed by radiotherapy and remain a therapeutic challenge. The role of
pharmacotherapy in all types of meningiomas remains controversial [3].
Current therapeutic approaches in individual patients include the vascular
endothelial growth factor (VEGF) antibody bevacizumab [6] ormultikinase
inhibitors such as sunitinib [7].
TG02, an oral cyclin-dependent kinase (CDK) inhibitor, is thought to
suppress tumor cell proliferation by depleting short-lived survival proteins
such as MCL-1 and c-MYC, which are transcribed by CDK9-dependent RNA
polymerase II [8]. TG02 exhibits preclinical activity in multiple tumor
models including glioma [9,10], and is currently in clinical development
for newly diagnosed and recurrent glioblastoma (NCT02942264, EORTC
1608/NCT03224104). Proliferative activity of meningiomas correlates
with WHO grade and only WHO grade II and III meningiomas were
shown to express MYC protein by immunohistochemistry [11,12]. More-
over, widespread expression of BCL-2 family proteins including MCL-1
has also been reported in meningiomas [13]. These data provided a ratio-
nale to explore the activity of TG02 in human meningioma models.
Methods
Materials and cell cultures
TG02 was kindly provided by Adastra (Carlsbad, CA), cisplatin and hy-
droxyurea were purchased from Sigma (St. Louis, MO). To establish
patient-derived meningioma models for in vitro drug testing, we adapted a
standard procedure used to derive glioma-initiating cell cultures
established in our laboratory [10]. Cell cultures were isolated from freshly
resected tumors after approval by the local ethics committee (2016-00456)
and obtaining informed patient consent. Briefly, tumor tissue was minced
and then digested with collagenase D (0.4 mg/ml) (Roche, Basel,
Switzerland) and DNase I (50 μl) (Sigma-Aldrich/Merck, Darmstadt,
Germany) in Dulbecco's modified Eagle's medium (DMEM) containing 2%
fetal calf serum (FCS) for 45 min at 37 °C. After incubation, further homog-
enization was performed by resuspension with an 18G needle. The solution
was filtered with a 70 μm mesh and washed with phosphate-buffered sa-
line. Cells were centrifuged, the supernatant was removed, and the pellet
was then cultured over three days in DMEM with 10% FCS, 1% glutamine
(10 μl/ml) (Invitrogen, Basel, Switzerland) and penicillin/streptomycin
(Sigma-Aldrich/Merck). On the third day, the medium was exchanged,
and cells were cultured and subsequently split. All cells used in this study
were sent for short tandem repeat analysis (DSMZ, Braunschweig,
Germany) and were tested for mycoplasma contamination.
Target inhibition and viability studies
Cell culture experimentswere conducted essentially as described for the
characterization of TG02 activity in glioma models [10]. Cell cultures of
passages 4 to 12 were used. In brief, TG02 target inhibition was assessed
by immunoblot using specific antibodies to phospho-RPB1, MCL-1 and c-
MYC (Cell Signaling Technology, Leiden, The Netherlands), using GAPDH
as a loading control. Protein bands were visualized using horseradish per-
oxidase (HRP)-coupled secondary antibodies (Santa Cruz Biotechnology,
Santacruz, CA) and enhanced chemiluminescence and quantified by
ImageJ software (Open Source). For growth inhibition studies using
TG02, cisplatin or hydroxyurea, the cells were seeded at a density of
40,000–50,000 cells perwell in 96well plates in serum-containingmedium
and exposed to serial drug dilutions 24 h thereafter, for a duration of 5 days,
depending on cell line-inherent growth patterns. Cell density was assessed
by MTT assay and EC50 values from 2 to 3 experiments were derived by
Graphpad.
Viability was directly interrogated after exposure to TG02 for 72 h by
annexin V (AnxV)/propidium iodide (PI) flow cytometry, using
staurosporine as a positive control. To determine specific cell cycle to
changes induced by TG02, the cells were fixed, permeabilized with cold
ethanol (70%), RNA was digested, and DNA was stained with PI. Senes-
cence was studied using the Senescence β-galactosidase Staining Kit (Cell
Signalling Technology) [10].
DNA methylation profiling
DNA was extracted from tumor tissue with tumor cell content >80% by
histopathological evaluation and from harvested cells using the automated
Maxwell system with the Maxwell 16 FFPE Plus LEV DNA Purification Kit
(Promega, Madison, WI, USA). DNA methylation profiling of all samples
was performed using the Infinium MethylationEPIC (850k) BeadChip
(Illumina, San Diego, CA, USA) or Infinium HumanMethylation450
(450k) BeadChip (Illumina) array [4].Methylation classes andmeningioma
methylation classes of the samples were identified as described [14]. Filter-
ing and genome-wide copy number analyses were performed as previously
described, using the ‘conumee’ package in R (http://www.bioconductor.
org) [15]. For illustration of DNA methylation data, t-distributed sn Neigh-
bor embedding (t-SNE) was performed as previously described [16] with
reference samples from [14]. Panel sequencing was performed with the
previously introduced brain tumor gene panel as described [17].
Statistical analysis
Technical and biological replicates were obtained. Results shown are
usually from representative experiments. For statistical analysis one-way
or two-way ANOVA with Bonferroni post-hoc testing (multiple compari-
sons) was performed.
Data availability
Data sets supporting the results in this study are available as “Supple-
mentary material”.
Results
Characterization of meningioma samples
Fig. 1 and Table 1 provide an overview of tumors included in this study.
Gene panel sequencing revealed several mutations known to be common in
meningiomas, along with few variants of unknown significance (Table S1).
850K methylation profiling and copy number analysis revealed that all
samples had highest scores for the methylation class “meningioma” and
could subsequently be assigned to known distinctmeningiomamethylation
classes [4]. The methylation classes and mutations resembled the
established associations: NF2mutations were found in cases of methylation
classes int-A/B and ben-1, while an activating SMO hotspot mutation was
detected in a case of methylation class ben-2 (Table 1).
We established cell cultures from these tumors and verified derivation
of the cell lines from the respective tumors [4]. Methylation classes of
tumor samples and cell cultures were identical for all four ben-2 tumors,
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Fig. 1. Characterization of meningioma models. A, representative T1-weighted, gadolinium-enhanced MRI; B, H&E staining of primary tumors; C, morphology of primary
cultures by phase contrast microscopy; D, illustration of alterations in copy number profiles calculated from methylation array data of tumor and derived cell line.
C. von Achenbach et al. Translational Oncology 13 (2020) 100852
3
Table 1
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⁎ radiation-induced meningioma: germinoma in 1979.































































































































































Fig. 2. Growth inhibition of meningioma models by TG02. A. Cells were exposed to TG02 at 135 or 405 nM for 24 h. Levels of pRNAPII, MCL-1 or c-MYC were assessed by
immunoblot. LN-229 glioma cells exposed to TG02 at 100 μM for 24 hwere used as a positive control. B. Specificity of the double c-MYC band in ZH-735 cells was explored by
c-myc gene silencing. C. Cell lines were exposed to TG02 for 120 h. Viability was assessed byMTT assay. Cells were exposed to cisplatin or hydroxyurea in parallel. Data are
expressed as metabolic activity relative to solvent control. D. ZH-739 cells were exposed to TG02 at 50 or 150 nM or to staurosporine (250 nM) for 72 h and analysed by
annexin V/PI flow cytometry. E. ZH-735 cells were treated accordingly and assessed by PI flow cytometry for DNA content.
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A, three of the derived cell cultures were classified asmalwhereas one was
classified as ben-2.
Copy number profiles derived from the methylation data are depicted in
Fig. 1D. Copy number status was identical in tissue and corresponding cell
sample in ZH-679, ZH-733, and ZH-739. Notably, the cell sample of ZH-
733 conserved a variety of chromosomal losses already detected in the tissue.
In ZH-706 and ZH-707, only small segmental alterations differed between tis-
sue and the respective cell sample. In ZH-696, ZH-719 and ZH-735, several
chromosomal alterations found in the tissue were not present in the cells. In
ZH-734, several alterations of the tissuewere preserved in the cells, but others
were lost during culturing. Focal alterations, e.g., amplification or homozy-
gous deletions, e.g., of CDKN2A or MYC were not detected in tumors or de-
rived cell lines. In general, copy number plots derived from cells were more
prone to artefact, which possibly obscured minor or subclonal alterations
(Fig. S1). Clustering of DNA methylation data of the cell lines and respective
tumor tissue along with reference samples for meningioma and other central
nervous system tumors, selected for histological differential diagnoses of me-
ningioma or sharing molecular features, e.g. NF2 mutation, confirmed that
the cells cluster with meningioma tissue (Fig. S2).
Sensitivity of meningioma cell cultures to TG02
Next, we explored direct and indirect target gene expression and its inhi-
bition by TG02 in selected cell line models. pRNAPII levels were suppressed
by TG02 in all models tested. MCL-1 levels varied profoundly among theme-
ningioma cell lines, but were uniformly reduced by TG02. As observed previ-
ously in glioma cell lines [10], changes in c-MYC levels in response to TG02
were less uniform (Fig. 2A). Specificity of the double c-MYC band in ZH-
735 was confirmed by c-myc gene silencing (Fig. 2B). TG02 resulted in a
concentration-dependent inhibition of meningioma cell proliferation across
all models, albeit withmajor variations which are summarized as EC50 values
in Table 1. Meningioma cells were overall less sensitive than glioma cells as
exemplified here by LN-229 [10], however, this may in part be attributed
to themuch slower growth of ex vivomeningioma cell cultures with doubling
times in the range of 5–15 days. The maximum growth inhibition achieved
with up to 300 μM TG02, a summary effect of growth inhibition and cell
loss by cytotoxicity, is also indicated. At the molar level, the activity of
TG02 was much stronger than cisplatin or hydroxyurea, two drugs occasion-
ally used in the pharmacotherapy of refractory meningioma, although with-
out relevant tumor control rates (Fig. 2C).
Annexin PI flow cytometry revealed overall little cell death induction
and no apparent role for apoptosis as the major cause of reduced cell den-
sity in TG02-treated cultures (Fig. 2D). Cell cycle analysis confirmed the ab-
sence of major cell death at concentrations of TG02 that induced profound
growth arrest; yet, there was an increase in the fraction of G2/Mcells. Inter-
estingly, aminor cell population treated with TG02 showed 4n and 8n DNA
content, indicative of failure to completemitosis after DNA replication, con-
sistent with mitotic catastrophe (Fig. 2E). We have previously reported
signs of senescence in TG02-treated glioblastoma cells [10]. Here we report
that ex vivomeningioma cell cultures exhibit high constitutive senescence-
associated β-galactosidase staining that was not enhanced by TG02. How-
ever, senescence was intensified by irradiation, a known inducer of senes-
cence (Fig. S3).
TG02 sensitivity and tumor classification
To allow an exploration of the relationships between sensitivity of TG02
and tumor characteristics, we arbitrarily set the EC50 value of the twomost
resistant cell lines to 300 nM although their true EC50 is known, but higher
than 300 nM. There was no uniform association of WHO grade of the tu-
mors and TG02 sensitivity of the cell lines except that none of the WHO
grade I tumor-derived cell lines was resistant to TG02 (Fig. 3A). There
was no difference between the groups (n= 4 each) of cell cultures derived
from tumors classified as ben-2 as opposed to int-A (Fig. 3B). In contrast, cell
lines assigned to the methylation classmal appeared to bemore sensitive to
TG02 than ben-2 cultures (Fig. 3C).
Discussion
Systemic treatment options for meningioma are urgently needed [3].
The identification of druggable pathogenicmutations in subsets ofmeningi-
omas [18–20], has renewed interest in pharmacotherapeutic approaches to
meningioma, but translation into the clinic remains challenging since me-
ningioma no longer amenable to local therapy is an orphan disease and
since some of the mutations found in meningioma have not been detected
and explored for intervention in other cancers. Particularly the most fre-
quent underlying mutation in meningioma, NF2, does not yet present an
immediate target. Also in our dataset, NF2 was the most prevalent alter-
ation and was enriched in the higher-grade cases of the more aggressive
methylation groups. Proof-of-concept has so far only obtained in one pa-
tient with AKTE177K-mutant meningioma [21] and others drug targets,
like SMO in one of our cases, are rare.
Here we established primary cell cultures of several meningiomas as
tools to explore pharmacological treatments in vitro. We characterized
these models in depth to estimate links betweenWHO grade versusmethyl-






































































































Fig. 3. Association between WHO grade an methylation based grade prediction of
primary tumor or derived cell cultures with TG02 sensitivity in vitro. EC50 values
for TG02 sensitivity of the cell lines are grouped (A) by WHO grade of the tumors
or (B) methylation based grade prediction of the tumors or (C) the cell cultures.
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noted that cell cultures from all ben-2 tumors exhibited the same methyla-
tion class as the primary tumors whereas as all non-ben-2 tumor-derived
cell cultures exhibited a shift in methylation class, with four of five cultures
assigned to a less benign methylation class. Still, the characteristic features
of meningioma remained detectable in the cell cultures as confirmed by t-
SNE clustering (Fig. S2).
We report that the novel cyclin-dependent kinase inhibitor, TG02,
shows activity in several patient-derived cell culture models of meningi-
omas of various WHO grades. Suppression of growth appears to be
primarily mediated through inhibition of proliferation rather than
acute induction of cell death. It is tempting to speculate that the more
prominent growth inhibition seen in cell cultures from less benign
tumors is related to their higher MYC levels [11,12], given that MYC
is an indirect target of TG02.
Limitations of our study include uncertainty regarding the representa-
tiveness of the derived cell cultures for the tumors, their likely contamina-
tion by non-tumor cells at least during initial passages, uncertainty
regarding the significance of differences between cultures and tumors in
terms ofmethylation class and copy number variations, and likely changing
drug sensitivity over time. Several lines ceased growth after weeks and
were no longer available for further studies, including in vivo studies. How-
ever, studies like ours are scarce, and patient-derived cell cultures are prob-
ably still the bestmodel available to explore novel drugs. Larger sample sets
are required to further interrogate the value of WHO grade versusmethyla-
tion based grade prediction in terms of predicting cell line responses in vitro.
Given the relentless, but mostly slow growth of meningiomas, such a pat-
tern of activity appears to make TG02 an interesting therapeutic candidate,
in a setting where almost no progress with pharmacotherapy has been
made in decades [3].
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.tranon.2020.100852.
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